Mayer Brown advises GW Pharmaceuticals plc and selling shareholders on $169.8 million Nasdaq offering
20 June 2014
Mayer Brown, a leading global law firm, represented GW Pharmaceuticals plc (GWP), a biopharmaceutical company, and selling shareholders in a $169.8 million US public offering of American Depositary Shares on the Nasdaq Global Market led by Morgan Stanley, BofA Merrill Lynch and Cowen and Company.
The transaction follows Mayer Brown’s representation of GWP on its US IPO in 2013, follow-on offering in January 2014 and the London office’s longstanding representation of GWP led by Corporate & Securities partners Peter Dickinson and Richard Smith.
The Mayer Brown team was led by Corporate & Securities partner David Bakst (New York) and included: Corporate & Securities – partner Richard Smith (London) and associates George Rudy (New York) and Vivian Chiu (London); Tax Transactions & Consulting – partners Jason Bazar (New York) and Sandy Bhogal (London) and associates Jared Goldberger (New York) and Benjamin Fryer (London); and Intellectual Property – partner Richard Assmus and associate Jonathan Kim (both Chicago).